FibroBiologics has filed with the U.S. Securities and Exchange Commission to raise $8,000,000.00 in an Initial Public Offering
According to filings with the U.S. Securities and Exchange Commission, FibroBiologics is raising $8,000,000.00 in new funding. About FibroBiologics: Our proprietary fibroblast platform serves as the foundation for developing biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal. Currently, FibroBiologics holds 150+ U.S. and International issued/pending patents across a variety of clinical pathways, including multiple sclerosis, cartilage repair, degenerative disc, cancer, wound healing, and extension of life programs. We have a distinguished board of directors and a scientific advisory board led by the industry’s top experts and key opinion leaders. Together, they bring years of experience to FibroBiologics that help shape strategy, guide the development of our products and our pipeline, and position our company for success.
To learn more about FibroBiologics, visit http://www.fibrobiologics.com/
Contact:
Pete OHeeron, Chief Executive Officer
281-671-5150
https://www.linkedin.com/in/peteoheeron/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.